However, given that high CCL2 and CCL7 expression is associated with poorer prognosis in GBM patients, consideration of the relative expression of these two chemokines may provide predictive value to a therapeutic strategy targeting this chemokine:chemokine receptor axis. This evidence concerns the gene CCL7 and glioblastoma.